Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 157

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 157
---
 molecular diagnostic tests could be impaired, and DiamiR may not be able to obtain coverage and adequate reimbursement for them. In the future, DiamiR may rely on third parties to process and transmit claims to payers for its clinical services, and any delay in processing or transmitting could have an adverse effect on its revenue and financial condition. As part of its future commercialization efforts, DiamiR may hire third parties to provide overall processing of claims and to transmit actual claims to payers based on specific payer billing formats. If claims for its clinical services are not submitted to payers on a timely basis, or if DiamiR is again required to switch to a different third -partyprocessor to handle claim submissions, DiamiR may experience delays in its ability to process claims and receive payment from payers, which could have a material adverse effect on its business, financial condition and results of operations. 75 DiamiR recognizes that there are inherent risks associated with third-party relationships, which may adversely affect its business. DiamiR expects to continue to depend on third -partyservice providers for the foreseeable future, but DiamiR recognizes that there are inherent risks associated with these third -partyrelationships. For example, its reputation may be harmed by allegations of wrong -doingsor violations of regulations by the third -partyservice providers. The security of its confidential and sensitive business information may be breached if the third -partyservice providers do not exercise high standard of care to guard and protect the information that comes to their possession because of the relationships with us. DiamiR does not have control over the amount of time and effort and level of care its third -partyservice providers will devote to performing their responsibilities under DiamiRs agreements with them. If DiamiR is unable to use or maintain its trademarks and trade names or build brand recognition in its markets of interest, its business may be adversely affected. DiamiR’s US Federal trademarks for the marks CogniMIR ®and DiamiR ®have been registered by the USPTO. If DiamiR does not maintain any registrations granted by the USPTO, DiamiR may encounter difficulty in continuing to use or enforce such trademarks. DiamiR’s trademarks or trade names may be challenged, infringed, circumvented, declared generic/descriptive or determined to be infringing on other marks. As a means to enforce its trademark rights and prevent infringement/dilution, DiamiR may be required to file trademark claims against third parties or initiate trademark